News

Vallourec's Voting Rights and Share Capital Overview Explained

Vallourec's Voting Rights and Share Capital Overview Explained

Overview of Vallourec's Shares and Voting Rights

VALLOUREC
French limited liability company with a Board of Directors.
Share capital stands at €4,761,692.46.

Meudon — This monthly report addresses essential information related to the number of voting rights and shares that constitute Vallourec's share capital. This information is provided in compliance with French regulatory requirements.

Legal Compliance

This disclosure is mandated by Article L. 233-8-II of the French Code de commerce and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF). These regulations are in place to ensure transparency and accountability to investors.

Current Voting Rights and Shares Data

The following summary showcases the number of outstanding shares along with the associated voting rights:

Date Total Outstanding Shares Theoretical Total Voting Rights Net Total Voting Rights
31 December 2024 238,084,623 233,917,225 233,917,225
30 November 2024 238,052,129 231,123,100 231,123,100
31 October 2024 238,052,129 231,051,893 231,051,893
30 September 2024 237,784,309 230,304,541 230,304,541
31 August 2024 237,784,309 230,244,702 230,244,702
31 July 2024 237,784,309 229,947,719 229,947,719
30 June 2024 237,271,828 229,877,070 229,769,402
31 May 2024 237,271,828 229,877,070 229,769,402
30 April 2024 237,271,828 229,877,070 229,769,402
31 March 2024 237,271,828 229,877,070 229,769,402
29 February 2024 237,271,828 229,877,070 229,769,402
31 January 2024 237,271,828 229,877,070 229,769,402
31 December 2023 237,271,828 229,877,070 229,769,402
30 November 2023 236,781,727 229,386,969 229,279,301
31 October 2023 236,781,727 229,386,969 229,279,301
30 September 2023 236,635,229 229,240,471 229,132,803
31 August 2023 236,619,061 229,240,471 229,132,803
31 July 2023 236,619,061 229,240,471 229,132,803
30 June 2023 235,532,187 229,240,471 229,132,803
31 May 2023 231,777,627 229,228,999 229,080,116
30 April 2023 231,777,627 229,228,999 229,080,116
31 March 2023 231,777,627 229,228,999 229,080,116
28 February 2023 231,777,627 229,228,999 229,080,116
31 January 2023 231,777,627 229,228,999 229,080,116
31 December 2022 231,777,627 229,228,999 229,080,116
30 November 2022 231,777,627 229,228,999 229,080,116
31 October 2022 231,777,627 229,228,999 229,080,116
30 September 2022 228,928,428 228,928,428 228,779,545
31 August 2022 228,928,428 228,928,428 228,779,545
31 July 2022 228,928,428 228,928,428 228,779,545
30 June 2022 228,928,428 228,928,428 228,779,502
31 May 2022 228,928,428 228,928,428 228,740,763
30 April 2022 228,928,428 228,928,428 228,740,763
31 March 2022 228,928,428 228,928,428 228,740,763
28 February 2022 228,928,428 228,928,428 228,740,763
31 January 2022 228,928,428 228,928,428 228,740,763
31 December 2021 228,928,428 228,928,428 228,740,763
30 November 2021 228,928,428 228,928,428 228,740,763
31 October 2021 228,928,428 228,928,428 228,740,763
30 September 2021 228,928,428 228,928,428 228,740,763
31 August 2021 228,928,428 228,928,428 228,740,763
31 July 2021 228,928,428 228,928,428 228,714,160
30 June 2021 228,928,428 228,928,428 228,914,031
31 May 2021 11,449,694 11,811,810 11,797,413
30 April 2021 11,449,694 11,811,772 11,790,691
31 March 2021 11,449,694 11,811,662 11,810,581
28 February 2021 11,449,694 11,809,473 11,808,392
31 January 2021 11,449,694 11,809,652 11,808,571
31 December 2020 11,449,694 11,810,456 11,809,375
30 November 2020 11,449,694 11,809,708 11,808,627
31 October 2020 11,449,694 11,809,929 11,808,848
30 September 2020 11,449,694 11,809,877 11,808,796
31 August 2020 11,449,694 11,792,317 11,791,236
31 July 2020 11,449,694 11,792,291 11,791,210
30 June 2020 11,449,694 11,792,487 11,791,352
31 May 2020 11,449,694 11,825,998 11,810,412
30 April 2020 457,987,760 467,246,708 466,723,205
31 March 2020 457,987,760 467,212,665 466,689,162
29 February 2020 457,987,760 470,490,431 469,966,928
31 January 2020 457,987,760 470,448,503 469,925,000
31 December 2019 457,987,760 470,435,812 469,912,309
30 November 2019 457,987,760 470,508,426 469,347,391
31 October 2019 457,987,760 470,087,934 469,373,397
30 September 2019 457,987,760 470,221,294 469,580,131
31 August 2019 457,987,760 470,814,057 469,958,130
31 July 2019 457,987,760 470,050,383 469,405,801
30 June 2019 457,987,760 470,450,701 469,139,005
31 May 2019 457,987,760 470,039,123 469,764,230
30 April 2019 457,987,760 470,054,532 469,728,212
31 March 2019 457,987,760 470,057,161 469,813,085

(1) The theoretical (or gross) number of voting rights includes shares temporarily deprived of voting rights, but excludes shares without voting rights.

(2) The net number of voting rights is calculated by excluding shares that do not carry voting rights. It is published for public information.

Regulatory Requirements

The by-laws of Vallourec dictate that any crossing of legal thresholds must be declared in addition to the legal requirements. This ensures transparency and maintains investor trust in the company.

Additional Information

For further insights and updates, stakeholders are encouraged to visit Vallourec's dedicated page for regulated information. This allows shareholders to stay informed about the company's latest announcements and compliance with regulations.

Frequently Asked Questions

1. What is Vallourec?

Vallourec is a French limited liability company specializing in manufacturing steel products and services for various industries.

2. How does Vallourec report its voting rights?

Vallourec reports its voting rights as part of its compliance with French regulations, providing monthly updates on outstanding shares and voting rights.

3. Why is the net voting rights number important?

The net voting rights number indicates the actual voting power available to shareholders during meetings, excluding shares that do not carry voting rights.

4. Where can I find more information on Vallourec’s shares?

Further information can be found on Vallourec's official website, specifically in the section dedicated to regulated information.

5. What happens if a shareholder crosses a threshold?

Shareholders are required to declare any crossing of thresholds as stipulated in Vallourec’s by-laws, ensuring transparency in ownership changes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 183

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 437

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 221

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading